Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 12, 2011, Pages 8944-8950

  Ramírez, Mayda ^a   Wu, Zhijian ^b   Moreno Carranza, Bibiana ^a   Jeziorski, Michael C ^a   Arnold, Edith ^a   Díaz Lezama, Nundehui ^a   de la Escalera, Gonzalo Martínez ^a   Colosi, Peter ^b   Clapp, Carmen ^a  

^a CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOASSOCIATED VIRUS TYPE 2 VASOINHIBIN VECTOR; EVANS BLUE; PARVOVIRUS VECTOR; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; ALBUMINOID; CELL CYCLE PROTEIN; COLORING AGENT; DEXTRAN; DRUG DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GREEN FLUORESCENT PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VASH1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DEGLYCOSYLATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RETINA BLOOD VESSEL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA GANGLION CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ADENO ASSOCIATED VIRUS; ANIMAL; CAPILLARY PERMEABILITY; CELL STRAIN HEK293; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE THERAPY; GENE TRANSFER; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; METHODOLOGY; PLASMID; RETINA HEMORRHAGE; WISTAR RAT;

ALBUMINS; ANIMALS; CAPILLARY PERMEABILITY; CELL CYCLE PROTEINS; COLORING AGENTS; DEPENDOVIRUS; DEXTRANS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; EVANS BLUE; FLUORESCEIN-5-ISOTHIOCYANATE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; INTRAVITREAL INJECTIONS; MALE; PLASMIDS; RATS; RATS, WISTAR; RETINAL HEMORRHAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856011422     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8190     Document Type: Article

References (56)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007-2008. Atlanta, GA: U.S. Department of Health and Human Services.
2. Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107:75-83, quiz 84.
3. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574-1580.
4. Clapp C, Thebault S, Arnold E, Garcia C, Rivera JC, de la Escalera GM. Vasoinhibins: novel inhibitors of ocular angiogenesis. Am J Physiol Endocrinol Metab. 2008;295:E772-E778.
5. Garcia C, Aranda J, Arnold E, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest. 2008;118:2291-2300.
6. Arnold E, Rivera JC, Thebault S, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010;59:3192-3197.
7. Clapp C, Thebault S, Jeziorski MC, Martinez de la Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev. 2009; 89:1177-1215.
8. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993;133:1292-1299.
9. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol. 2000; 14:1536-1549.
10. Duenas Z, Rivera JC, Quiroz-Mercado H, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci. 2004;45:2049-2055.
11. Pan H, Nguyen NQ, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2004;45:2413-2419.
12. Triebel J, Huefner M, Ramadori G. Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy. Eur J Endocrinol. 2009;161:345-353.
13. Auricchio A, Rolling F. Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases. Curr Gene Ther. 2005;5:339-348.
14. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med. 2009;15:23-31.
15. Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003;102:2412-2419.
16. Aranda J, Rivera JC, Jeziorski MC, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005;46:2947-2953.
17. Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes. 2007;56:2380-2387.
18. Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors. Methods. 2002;28:267-275.
19. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001;42:789-794.
20. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev. 1995;16:354-369.
21. Kim J, Luo W, Chen DT, et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 2003;63:386-393.
22. Hellstrom M, Ruitenberg MJ, Pollett MA, et al. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther. 2009; 16:521-532.
23. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003; 19:442-455.
24. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712.
25. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
26. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284.
27. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118:609-614.
28. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
29. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Muller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol. 2007;245:627-636.
30. Xu HZ, Le YZ. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Invest Ophthalmol Vis Sci. 2011; 52:2160-2164.
31. Gonzalez C, Corbacho AM, Eiserich JP, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology. 2004;145:5714-5722.
32. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA. 2001;98:2604-2609.
33. Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology. 1992;130:1380-1386.
34. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
35. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113:294-301.
36. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:3784-3791.
37. Elayappan B, Ravinarayannan H, Pasha SP, Lee KJ, Gurunathan S. PEDF inhibits VEGF-and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis. 2009;12:313-324.
38. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13:181-188.
39. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev. 2010;6:304-312.
40. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224-230.
41. Ambati J. A molecular understanding of macular edema. Adv Stud Ophthalmol. 2007;4:179-181.
42. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366-1369.
43. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122:1801-1807.
44. Hernandez C, Fonollosa A, Garcia-Ramirez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028-2033.
45. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13:1275-1293.
46. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogenactivated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA. 1995;92:6374-6378.
47. Lee SH, Kunz J, Lin SH, Yu-Lee LY. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res. 2007;67:11045-11053.
48. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol. 1999;13:537-545.
49. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324-328.
50. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003;14:129-141.
51. Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med. 2007;19:75-79.
52. Rolling F. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives. Gene Ther. 2004;11(suppl 1):S26-S32.
53. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009; 20:999-1004.
54. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 2001;61:7356-7362.
55. Nguyen NQ, Cornet A, Blacher S, et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther. 2007;15:2094-2100.
56. Tabruyn SP, Sabatel C, Nguyen NQ, et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-+B activation. Mol Endocrinol. 2007;21:1422-1429.